Xeris Biopharma Holdings, Inc. updated product revenue guidance for the full year 2022. It has updated its outlook for full year 2022 expecting net product revenue to be at the top of its guidance range of $105 million to $110 million and its year-end cash balance to be above the previously announced range of $110 million to $120 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | +3.63% |
|
+18.98% | +9.36% |
08/07 | Xeris Biopharma Appoints John Shannon as CEO | MT |
08/07 | Xeris Biopharma Holdings, Inc. Announces CEO Changes | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.36% | 38Cr | |
+61.53% | 85TCr | |
+32.70% | 63TCr | |
-3.66% | 36TCr | |
+15.06% | 32TCr | |
+9.18% | 30TCr | |
+13.38% | 24TCr | |
+16.43% | 23TCr | |
+15.67% | 18TCr | |
+2.47% | 17TCr |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Updates Product Revenue Guidance for the Full Year 2022